Incidence of exposure of patients in the United States to multiple drugs for which pharmacogenomic guidelines are available

Matthias Samwald, Hong Xu, Kathrin Blagec, Philip E. Empey, Daniel C Malone, Seid Mussa Ahmed, Patrick Ryan, Sebastian Hofer, Richard D. Boyce

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Pre-emptive pharmacogenomic (PGx) testing of a panel of genes may be easier to implement and more cost-effective than reactive pharmacogenomic testing if a sufficient number of medications are covered by a single test and future medication exposure can be anticipated. We analysed the incidence of exposure of individual patients in the United States to multiple drugs for which pharmacogenomic guidelines are available (PGx drugs) within a selected four-year period (2009-2012) in order to identify and quantify the incidence of pharmacotherapy in a nation-wide patient population that could be impacted by pre-emptive PGx testing based on currently available clinical guidelines. In total, 73 024 095 patient records from private insurance, Medicare Supplemental and Medicaid were included. Patients enrolled in Medicare Supplemental age > = 65 or Medicaid age 40-64 had the highest incidence of PGx drug use, with approximately half of the patients receiving at least one PGx drug during the 4 year period and one fourth to one third of patients receiving two or more PGx drugs. These data suggest that exposure to multiple PGx drugs is common and that it may be beneficial to implement wide-scale pre-emptive genomic testing. Future work should therefore concentrate on investigating the cost-effectiveness of multiplexed pre-emptive testing strategies.

Original languageEnglish (US)
Article numbere0164972
JournalPLoS One
Volume11
Issue number10
DOIs
StatePublished - Oct 1 2016

Fingerprint

pharmacogenomics
Pharmacogenetics
Guidelines
incidence
drugs
Incidence
Pharmaceutical Preparations
Testing
testing
Medicaid
Medicare
drug therapy
Drug therapy
insurance
Insurance
cost effectiveness
Cost effectiveness
Cost-Benefit Analysis
concentrates
Genes

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Incidence of exposure of patients in the United States to multiple drugs for which pharmacogenomic guidelines are available. / Samwald, Matthias; Xu, Hong; Blagec, Kathrin; Empey, Philip E.; Malone, Daniel C; Ahmed, Seid Mussa; Ryan, Patrick; Hofer, Sebastian; Boyce, Richard D.

In: PLoS One, Vol. 11, No. 10, e0164972, 01.10.2016.

Research output: Contribution to journalArticle

Samwald, Matthias ; Xu, Hong ; Blagec, Kathrin ; Empey, Philip E. ; Malone, Daniel C ; Ahmed, Seid Mussa ; Ryan, Patrick ; Hofer, Sebastian ; Boyce, Richard D. / Incidence of exposure of patients in the United States to multiple drugs for which pharmacogenomic guidelines are available. In: PLoS One. 2016 ; Vol. 11, No. 10.
@article{5d8b474e88764c9a85ef954e0b40f42f,
title = "Incidence of exposure of patients in the United States to multiple drugs for which pharmacogenomic guidelines are available",
abstract = "Pre-emptive pharmacogenomic (PGx) testing of a panel of genes may be easier to implement and more cost-effective than reactive pharmacogenomic testing if a sufficient number of medications are covered by a single test and future medication exposure can be anticipated. We analysed the incidence of exposure of individual patients in the United States to multiple drugs for which pharmacogenomic guidelines are available (PGx drugs) within a selected four-year period (2009-2012) in order to identify and quantify the incidence of pharmacotherapy in a nation-wide patient population that could be impacted by pre-emptive PGx testing based on currently available clinical guidelines. In total, 73 024 095 patient records from private insurance, Medicare Supplemental and Medicaid were included. Patients enrolled in Medicare Supplemental age > = 65 or Medicaid age 40-64 had the highest incidence of PGx drug use, with approximately half of the patients receiving at least one PGx drug during the 4 year period and one fourth to one third of patients receiving two or more PGx drugs. These data suggest that exposure to multiple PGx drugs is common and that it may be beneficial to implement wide-scale pre-emptive genomic testing. Future work should therefore concentrate on investigating the cost-effectiveness of multiplexed pre-emptive testing strategies.",
author = "Matthias Samwald and Hong Xu and Kathrin Blagec and Empey, {Philip E.} and Malone, {Daniel C} and Ahmed, {Seid Mussa} and Patrick Ryan and Sebastian Hofer and Boyce, {Richard D.}",
year = "2016",
month = "10",
day = "1",
doi = "10.1371/journal.pone.0164972",
language = "English (US)",
volume = "11",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "10",

}

TY - JOUR

T1 - Incidence of exposure of patients in the United States to multiple drugs for which pharmacogenomic guidelines are available

AU - Samwald, Matthias

AU - Xu, Hong

AU - Blagec, Kathrin

AU - Empey, Philip E.

AU - Malone, Daniel C

AU - Ahmed, Seid Mussa

AU - Ryan, Patrick

AU - Hofer, Sebastian

AU - Boyce, Richard D.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Pre-emptive pharmacogenomic (PGx) testing of a panel of genes may be easier to implement and more cost-effective than reactive pharmacogenomic testing if a sufficient number of medications are covered by a single test and future medication exposure can be anticipated. We analysed the incidence of exposure of individual patients in the United States to multiple drugs for which pharmacogenomic guidelines are available (PGx drugs) within a selected four-year period (2009-2012) in order to identify and quantify the incidence of pharmacotherapy in a nation-wide patient population that could be impacted by pre-emptive PGx testing based on currently available clinical guidelines. In total, 73 024 095 patient records from private insurance, Medicare Supplemental and Medicaid were included. Patients enrolled in Medicare Supplemental age > = 65 or Medicaid age 40-64 had the highest incidence of PGx drug use, with approximately half of the patients receiving at least one PGx drug during the 4 year period and one fourth to one third of patients receiving two or more PGx drugs. These data suggest that exposure to multiple PGx drugs is common and that it may be beneficial to implement wide-scale pre-emptive genomic testing. Future work should therefore concentrate on investigating the cost-effectiveness of multiplexed pre-emptive testing strategies.

AB - Pre-emptive pharmacogenomic (PGx) testing of a panel of genes may be easier to implement and more cost-effective than reactive pharmacogenomic testing if a sufficient number of medications are covered by a single test and future medication exposure can be anticipated. We analysed the incidence of exposure of individual patients in the United States to multiple drugs for which pharmacogenomic guidelines are available (PGx drugs) within a selected four-year period (2009-2012) in order to identify and quantify the incidence of pharmacotherapy in a nation-wide patient population that could be impacted by pre-emptive PGx testing based on currently available clinical guidelines. In total, 73 024 095 patient records from private insurance, Medicare Supplemental and Medicaid were included. Patients enrolled in Medicare Supplemental age > = 65 or Medicaid age 40-64 had the highest incidence of PGx drug use, with approximately half of the patients receiving at least one PGx drug during the 4 year period and one fourth to one third of patients receiving two or more PGx drugs. These data suggest that exposure to multiple PGx drugs is common and that it may be beneficial to implement wide-scale pre-emptive genomic testing. Future work should therefore concentrate on investigating the cost-effectiveness of multiplexed pre-emptive testing strategies.

UR - http://www.scopus.com/inward/record.url?scp=84992365383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992365383&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0164972

DO - 10.1371/journal.pone.0164972

M3 - Article

C2 - 27764192

AN - SCOPUS:84992365383

VL - 11

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 10

M1 - e0164972

ER -